Cantargia Reports Promising Early Remissions with Nadunolimab in High-Risk MDS and AML Trial

Cantargia AB ( (SE:CANTA) ) has shared an announcement.

Cantargia has reported early data from an ongoing Phase 1b/2a trial of its IL1RAP-targeting antibody nadunolimab in high-risk myelodysplastic syndrome and acute myelogenous leukemia, where it is combined with azacitidine, or azacitidine plus venetoclax. The completed Phase 1b dose-escalation stage in 12 patients showed the combinations were generally well tolerated with an acceptable safety profile.

In the high-risk MDS cohort, five efficacy-evaluable patients all achieved complete remission, with a sixth pending evaluation, suggesting a strong preliminary signal of activity in a setting of high unmet need. The investigator-initiated study at MD Anderson Cancer Center will expand to about 40 patients in Phase 2a during 2026, potentially broadening the clinical footprint of nadunolimab and reinforcing Cantargia’s positioning in IL1RAP-targeted oncology if results hold up in a larger population.

The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK14.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.

More about Cantargia AB

Cantargia AB is a Swedish clinical-stage biotechnology company developing antibody-based treatments for life‑threatening diseases using a platform targeting the IL1RAP protein, which is implicated in various cancers and inflammatory conditions. Its lead oncology antibody nadunolimab (CAN04) is being tested primarily with chemotherapy in pancreatic cancer and non-small cell lung cancer, while a second antibody program, CAN10, targeting autoimmune and inflammatory diseases, was acquired by Otsuka Pharmaceutical in 2025.

YTD Price Performance: -10.01%

Average Trading Volume: 1,818,467

Technical Sentiment Signal: Hold

Current Market Cap: SEK936.3M

For a thorough assessment of CANTA stock, go to TipRanks’ Stock Analysis page.